Utilizing natural defence mechanisms:
Developing effective drugs and treatments against respiratory viral infections
By rethinking treatments against respiratory viral infections, Pharma Holdings is championing intranasal virucidal products that will reduce the risk of severe infections for patients globally.
Our mission
Pharma Holdings is a lean and cost-effective organization using high-quality contract research organizations and contract development and manufacturing organizations, as well as highly experienced advisors. Our innovative nasal spray product targets early viral infections via a rapid and selective virucidal effect in the nose.
Our mission is to is to develop highly effective drugs and treatments for respiratory viral infections, that will reduce the risk of severe complications.
